by Portfolio Grader | December 25, 2013 8:00 am
This week, five biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
ARIAD Pharmaceuticals, Inc. (ARIA) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. The stock price has risen 25.3% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
Neurocrine Biosciences, Inc. (NBIX) boosts its rating from a C to a B this week. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The stock’s price of $9.63 is above the 50-day moving average of $9.56. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
This week, Array BioPharma (ARRY) pushes up from a C to a B rating. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
This week, Celldex Therapeutics, Inc. (CLDX) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. For more information, get Portfolio Grader’s complete analysis of CLDX stock.
This is a strong week for Insmed Incorporated (INSM). The company’s rating climbs to B from the previous week’s C. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. Investors seem to agree with the upgraded status of the stock and have pushed the stock up 5.4% over the past month. For more information, get Portfolio Grader’s complete analysis of INSM stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/12/5-biotechnology-stocks-to-buy-now-aria-nbix-arry-22/
Short URL: http://invstplc.com/1nv5IWf
Copyright ©2015 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.